

COMPANY MILESTONES

2016	Plant extension in Canada. Qilib is launched in the U.S. Expansion of Distribution agreement for Dysport to key areas in Asia.	2006	Clobex Spray launch in the U.S. Opening of the new Galderma R&D center in Sophia Antipolis
2015	Galderma enters neutraceutical market with acquisition of certain Innéov assets. Opening of branch office/MEA regional headquarters in Dubai. Launch of Soolantra cream 1% (rosacea) in the U.S. and Europe. Launch of Epiduo Forte Gel, 0.3%/2.5% in the U.S.	2005	Metrogel 1% launch in the U.S. Galderma becomes number one* in the D class (Dermatology) <small>*source: IMS Health, IMS dataview – D class – MAT Q3 2005 – 33 countries).</small>
2014	Foundation of Nestlé Skin Health. Galderma is now fully-owned by Nestlé. Galderma commercializes Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada.	2004	Opening of a new production site in Hortolandia, Brazil. Clobex Shampoo launch in the U.S. and acquisition of Tri-Luma.
2013	Acquisition of Swiss company Spirig Pharma AG, manufacturer of Daylong & Excipial. FDA approval of Mirvaso for the treatment of erythema associated with rosacea.	2003	Launch of Metvix in Germany and the UK and Clobex Lotion (psoriasis) in the U.S. Restylane is approved in the U.S.
2012	Galderma defines its new 3-business strategy and a new ambition statement. Opening of a new affiliate in China. Cetaphil Dermacontrol is launched in 6 countries.	2001	Licensing agreement for Metvix (skin cancer).
2011	Acquisition of Q-Med, a Swedish company specialized in aesthetic & corrective solutions. Emervel (dermal filler range) launch in Europe and Latin America. Plant extensions in France and Canada.	2000	The Montreal production unit comes on stream. Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis).
2010	Galderma hits the 1 billion € mark in sales. Launch of Cetaphil Restoraderm. Differin Lotion 0.1% (acne) launch in the U.S. Launch of Restylane Skincare series with NASHA.	1999	Acquisition of Loceryl (fungal nail infections), developed by F. Hoffmann-La Roche Ltd, together with the Scandinavian dermatology portfolio developed by Nycomed.
2009	Launch of Vectical (psoriasis), Azzalure (glabellar lines) and Restylane Injector, an innovative type of injection device. Galderma purchases global rights, assets and liabilities related to Metvix and Aktilite. Restylane obtains registration approval in China and becomes the first injectable non-animal hyaluronic acid product on the Chinese market.	1998	Inauguration of a new R&D facility in Princeton, New Jersey, U.S.
2008	Launch of Epiduo (acne). Acquisition of CollaGenex Pharmaceuticals and its product Oracea (rosacea). Launch of Differin 0.1% Gel in Japan.	1996	Acquisition of a plant belonging to Wyeth-Ayerst in Montreal, Canada, to develop a state-of-the-art manufacturing plant. Restylane is approved for sale in Europe, for filling out of wrinkles and lip augmentation.
2007	License agreements for Pliaglis (topical anesthetic) and a botulinum toxin Type A. Launch of Differin 0.3%.	1995	Launch of acne treatment Differin, Galderma's first home-grown dermatology product. The NASHA patent is filed.
		1994	Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.
		1993	Acquisition of MetroGel/Rozex to include rosacea treatments in the product portfolio. Launch of Daylong by Spirig Pharma.
		1989	New affiliates open in Canada, Germany, Spain and the UK.
		1988	Galderma takes over Alcon's dermatology business.
		1987	Q-Med is founded by Bengt Ågerup to commercialize the research that he had carried out around hyaluronic acid.

- 1986** Galderma's first operations open for business in France, followed by a second affiliate in Italy.
- 1981** **Nestlé and L'Oréal form a joint venture – Galderma – to become the world's leading dermatology player.**
- 1979** L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia Antipolis, France, specializing in fundamental research into skin physiology.
- 1977** Nestlé acquires Alcon.
- 1972** Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.
Launch of Excipial by Spirig Pharma.
- 1961** Creation of the Owen dermatology company in Dallas, Texas, U.S.
- 1948** Creation of Spirig Pharma in Olten, Switzerland.